TY  - JOUR
AU  - van Schaik, Ivo N
AU  - Mielke, Orell
AU  - Bril, Vera
AU  - van Geloven, Nan
AU  - Hartung, Hans-Peter
AU  - Lewis, Richard A
AU  - Sobue, Gen
AU  - Lawo, John-Philip
AU  - Praus, Michaela
AU  - Durn, Billie L
AU  - Cornblath, David R
AU  - Merkies, Ingemar S J
AU  - PATH study group
PY  - 2019
DO  - 10.1212/NXI.0000000000000590
UR  - https://hdl.handle.net/10668/27338
T2  - Neurology(R) neuroimmunology & neuroinflammation
AB  - To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). In a 48-week open-label prospective extension study to the PATH study, patients were...
LA  - en
KW  - Adult
KW  - Aged
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunoglobulin G
KW  - Immunoglobulins, Intravenous
KW  - Injections, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
KW  - Prospective Studies
KW  - Time Factors
KW  - Treatment Outcome
TI  - Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
TY  - research article
VL  - 6
ER  -